mohamad eftekhary

Dr. mohamad eftekhary

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
HGHossein Ghanbarian
Hossein Ghanbarian
SAShahin Aghamiri
Shahin Aghamiri
MEmohamad eftekhary
mohamad eftekhary
Nicole WagnerNicole Wagner
Nicole Wagner
Kay-Dietrich WagnerKay-Dietrich Wagner
Kay-Dietrich Wagner
Small double-strand RNA (dsRNA) molecules can activate endogenous genes via an RNA-based promoter targeting mechanism. RNA activation (RNAa) is an evolutionarily conserved mechanism present in diverse eukaryotic organisms ranging from nematodes to humans. Small activating RNAs (saRNAs) involved in RNAa have been successfully used to activate gene expression in cultured cells, and thereby this emergent technique might allow us to develop various biotechnological applications, without the need to synthesize hazardous construct systems harboring exogenous DNA sequences. Accordingly, this thematic issue aims to provide insights into how RNAa cellular machinery can be harnessed to activate gene expression leading to a more effective clinical treatment of various diseases.

2 September 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
RAReza Alimohammadi
Reza Alimohammadi
MPMeysam Porgoo
Meysam Porgoo
MEmohamad eftekhary
mohamad eftekhary
SKSeyed Hossein Kiaie
Seyed Hossein Kiaie
EDEhsan Ansari Dezfouli
Ehsan Ansari Dezfouli
VKVahid Khoddami
Vahid Khoddami
At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN®; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2 × 108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.

10 April 2024 in Journal of Industrial and Engineering Chemistry
Verified
Journal Article
Open access
SJSaeed Jafarkhani
Saeed Jafarkhani
EAElahe Amiri
Elahe Amiri
TZToktam Zohoorian-Abootorabi
Toktam Zohoorian-Abootorabi
HMHanieh Moris
Hanieh Moris
MEmohamad eftekhary
mohamad eftekhary
Mehrdad KhakbizMehrdad Khakbiz
Mehrdad Khakbiz

7 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RAReza Alimohammadi
Reza Alimohammadi
MPMeysam Porgoo
Meysam Porgoo
MEmohamad eftekhary
mohamad eftekhary
SKSeyed Hossein Kiaie
Seyed Hossein Kiaie
EDEhsan Ansari Dezfouli
Ehsan Ansari Dezfouli
VKVahid Khoddami
Vahid Khoddami
At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN ® ; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN ® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN ® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2×10 8 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN ® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.